Result of AGM

RNS Number : 9956D

MaxCyte, Inc.

02 November 2020

 

Result of AGM

Gaithersburg, Maryland - 02 November 2020:   MaxCyte (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, announces that at its Annual General Meeting held on 30^th October 2020, all resolutions were duly passed.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit  www.maxcyte.com .

###

Contacts:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer	[phone]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden	[phone]
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith	[phone]
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh --------------------------------------------------------------	[phone] [e-mail]

 

END

 

 

RAGBUBDBGUGDGGD